OCA Ventures

OCA Ventures is a Chicago-based early-stage venture capital firm with a long-running practice across software, financial services, and, increasingly, healthcare. The firm has been investing for more than two decades and has built a reputation for backing founders in markets where structural inefficiencies create durable opportunities for software and data-driven platforms to take share.

In healthcare, OCA’s thesis centers on digital health, health IT, and diagnostics, with a clear preference for companies that drive structural efficiencies in the clinical landscape rather than incremental improvements. Portfolio companies including Amplified Sciences, a diagnostics platform focused on early disease detection, and eBlu Solutions, a specialty medication management platform for clinics, illustrate the range. The firm tends to invest where AI, software, and data infrastructure converge with regulated clinical environments, which requires patience for longer go-to-market cycles but produces defensible market positions when execution lands.

OCA invests at Seed, Series A, and Series B with check sizes of $1M to $5M. The firm focuses primarily on U.S.-based founders and is comfortable with companies based outside coastal hubs, reflecting Chicago’s broader role as a venture market that values capital efficiency. Founders evaluating OCA should expect a partner who is willing to lead seed rounds and participate meaningfully in early A rounds, with continued follow-on support tied to milestone achievement.

The team is partner-led and lean, with investment professionals who bring backgrounds across operating roles, financial services, and venture investing. Decisions move through a focused partnership without committee theatrics, and founders typically receive direct feedback on a manageable timeline. The diligence process is rigorous around unit economics, contract structure, and regulatory pathway, particularly for diagnostics and clinical software bets.

OCA’s working style is grounded and pragmatic, in keeping with its Midwestern base. The firm is comfortable backing technical founders who are deep in their domain and expects a clear thesis on how the company will scale beyond its initial wedge. Portfolio founders describe partners who engage substantively on commercial strategy, hiring, and follow-on positioning without micromanaging operations. Board engagement is typical at the earliest stages, with formal cadences settling into quarterly rhythm post-Series A. The firm participates actively in syndicates and is comfortable both leading and following depending on stage and conviction. For healthcare founders specifically, OCA brings a network of Midwest health system relationships and an ability to make introductions to specialty pharmacy and clinical-research partners that can accelerate early commercial validation. Founders who fit best at OCA are those who can demonstrate a defensible technical or operational moat, articulate a credible path to repeatable revenue, and value a partner who treats venture capital as a long-term working relationship rather than a transactional event.